Answer
Mylotarg (gemtuzumab ozogamicin) moderately influences driving and machinery use and may cause fatigue, dizziness and headache during treatment, so patients should exercise caution when driving or operating machinery.
Sources for this answer
- MYLOTARG 5mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.7 Effects on ability to drive and use machines · Version 13Document updated
Sources checked